August 13, 2024 03:00 PM EDT
R&D

Rivus posts a win for its ex­per­i­men­tal obe­si­ty drug in heart fail­ure pa­tients

Max Bayer

Pharma Reporter

Rivus Phar­ma­ceu­ti­cals’ ex­per­i­men­tal car­diometa­bol­ic drug, HU6, nailed a mid-stage tri­al in obese pa­tients with heart fail­ure, find­ing that pa­tients notched a sta­tis­ti­cal­ly sig­nif­i­cant re­duc­tion in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

A service from the Financial Times